Phase II trial of edatrexate in patients with metastatic colorectal cancer

Gerald H. Clamon, Charles E. Riggs, Robert Dreicer, Raymond J. Hohl

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Edatrexate is an analog of methotrexate which in vitro demonstrated activity against human colon cancer xenografts grown in nude mice. In a phase II trial, 12 patients with metastatic colorectal cancer and no prior chemotherapy were treated with Edatrexate 80 mg/m2/week for an initial period of 8 weeks. No objective responses were observed. Edatrexate is inactive against colon cancer at the dose and schedule used in this trial.

Original languageEnglish (US)
Pages (from-to)359-361
Number of pages3
JournalInvestigational New Drugs
Volume13
Issue number4
DOIs
StatePublished - Dec 1 1995

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of edatrexate in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this